Gt biopharma advances gtb-3650 phase 1 trial to cohort 2 following successful initial human dosing and evidence of early immune activation signals

Following the formal safety review of cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with cohort 2.
GTBP Ratings Summary
GTBP Quant Ranking